Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer

McDonnell, Ciarán; Bouchier‐Hayes, David; Toomey, Deirdre; Foley, Deirdre; Kay, Elaine W.; Leen, Eamonn; Walsh, T. N.

doi:10.1002/bjs.4338

Cited by 20 publications

(11 citation statements)

References 31 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a previous study conducted by McDonnell et al, it was revealed that the mean microvessel density was 6.4 per high-power field in tumors that received preoperative treatment compared with 5.3 per high-power field in those treated by surgery alone. 42 The authors argued that the reactive inflammatory changes occurring in a tumor following chemotherapy may induce an increase in the macrophage population, which in turn results in a persistently high VEGF production, as well as a raised microvessel density. This finding seems to be a reasonable explanation for our findings.…”

Section: Discussionmentioning

confidence: 99%

Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer

Yao²,

Liu³

et al. 2007

Cancer Biology & Therapy

View full text Add to dashboard Cite

Quantitative or semi-quantitative analysis of fluorine-18 fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) has been reported to correlate with the clinical and pathological response of tumors to preoperative treatment. This study was conceived to evaluate the correlation between hybrid 18 F-FDG PET/CT and apoptosis in breast cancer after neoadjuvant chemotherapy. Three cycles of neoadjuvant chemotherapy were given to forty-five patients with primary breast cancer proven by core needle biopsy. Hybrid PET/CT was performed before and after treatment and tumor to non-tumor radioactivity ratio (T/N) was calculated. The apoptotic index (AI) in core-cut and surgically resected samples was determined using TUNEL techniques. The mean T/N pre-and postchemotherapy was 3.23 ± 0.63 and 2.31 ± 0.49, respectively (p = 0.006), with the mean reduction rate below baseline of 31.18 ± 13.18% (range, 6.4-50.8%). The mean AI pre-and post-chemotherapy was 2.81 ± 0.76% and 17.31 ± 6.85%, respectively (p < 0.0001). The mean AI change was 14.34 ± 5.36% (range, 1.9-41.3%). A positive correlation was detected between the T/N reduction rate and AI change (r s = 0.850, p < 0.0001). At a threshold of 20% decrease from baseline in T/N, the mean AI change in the tumors with a reduction of 20% or more in T/N was 20.86 ± 4.29%, while that in the tumors with a reduction of less than 20% in T/N was 8.59 ± 2.87% (p < 0.0001). The sensitivity, specificity, positive and negative predictive values, and the accuracy of PET/CT for the prediction of clinical response were 90.9%, 83.3%, 93.8%, 76.9% and 92%, respectively. These data suggested that neoadjuvant chemotherapy may effectively induce apoptosis in breast tumors and decrease their glucose uptake. Hybrid PET/CT imaging appeared to be positively related to apoptosis level and therefore to be of value in predicting the response of breast cancer to neoadjuvant chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer

Yao²,

Liu³

et al. 2007

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Great progress has been made in developing therapeutic strategies that target TAMs and VEGF to treat cancer (Kim et al, 1993). Several studies have revealed that TAMs are a very critical cell group in tumor tissue and that TAMs contribute greatly to tumorigenesis and the protection of tumors from therapy (McDonnell et al, 2003). VEGF inhibition represses tumor angiogenesis, and this result has led to the clinical utilization of VEGF inhibitors to treat cancer (Warren et al, 1995;Presta et al, 1997).…”

Section: Microvesicle-delivered Mir-150 Inhibitor Prevents Tumorigenesismentioning

confidence: 99%

Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development

et al. 2013

View full text Add to dashboard Cite

“…Tew,Kelsen,Ilson 597 Given that most patients with locally advanced esophageal cancer are treated with concurrent chemoradiation, there may be a possible integrative role for VEGF blockade. Neoadjuvant chemoradiation has a minimal effect on the angiogenic tumor profile (VEGF, von Willebrand factor, CD68, macrophage infiltration), portending a bad prognosis [114]. VEGF blockade reduces tumor interstitial pressure and vascular permeability, thus enhancing radiation and delivery of chemotherapy to tumors [115,116].…”

Section: Vegf Mabsmentioning

confidence: 99%

Targeted Therapies for Esophageal Cancer

2005

View full text Add to dashboard Cite

Esophageal cancer is a highly aggressive neoplasm. In 2005, 14,520 Americans will be diagnosed with esophageal cancer, and more than 90% will die of their disease. On a global basis, cancer of the esophagus is the sixth leading cause of cancer death worldwide. In fact, gastric and esophageal cancers together accounted for nearly 1.3 million new cases and 980,000 deaths worldwide in 2000-more than lung, breast, or colorectal cancer. Although esophageal squamous cell carcinoma cases have steadily declined, the incidence of gastroesophageal junction adenocarcinoma has increased 4%-10% per year among U.S. men since 1976, more rapidly than for any other cancer type, and parallels rises in population trends in obesity and reflux disease. With advances in surgical techniques and treatment, the prognosis of esophageal cancer has slowly improved over the past three decades. However, the 5-year overall survival rate (14%) remains poor, even in comparison with the dismal survival rates (4%) from the 1970s. The underlying reasons for this disappointingly low survival rate are multifold: (a) ineffective screening tools and guidelines; (b) cancer detection at an advanced stage, with over 50% of patients with unresectable disease or distant metastasis at presentation; (c) high risk for recurrent disease after esophagectomy or definitive chemoradiotherapy; (d) unreliable noninvasive tools to measure complete response to chemoradiotherapy; and (e) limited survival achieved with palliative chemotherapy alone for patients with metastatic or unresectable disease. Clearly, additional strategies are needed to detect esophageal cancer earlier and to improve our systemic treatment options. Over the past decade, the field of drug development has been transformed with the identification of and ability to direct treatment at specific molecular targets. This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma. The Oncologist 2005:590-601Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer

Cited by 20 publications

References 31 publications

Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer

Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer

Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development

Targeted Therapies for Esophageal Cancer

Contact Info

Product

Resources

About